142 related articles for article (PubMed ID: 19236235)
1. Paradoxical role for adiponectin in chronic renal diseases? An example of reverse epidemiology.
Beige J; Heipmann K; Stumvoll M; Körner A; Kratzsch J
Expert Opin Ther Targets; 2009 Feb; 13(2):163-73. PubMed ID: 19236235
[TBL] [Abstract][Full Text] [Related]
2. Plasma adiponectin levels for prediction of cardiovascular risk among hemodialysis patients.
El-Shafey EM; Shalan M
Ther Apher Dial; 2014 Apr; 18(2):185-92. PubMed ID: 24720410
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.
Zoccali C; Mallamaci F; Tripepi G; Benedetto FA; Cutrupi S; Parlongo S; Malatino LS; Bonanno G; Seminara G; Rapisarda F; Fatuzzo P; Buemi M; Nicocia G; Tanaka S; Ouchi N; Kihara S; Funahashi T; Matsuzawa Y
J Am Soc Nephrol; 2002 Jan; 13(1):134-141. PubMed ID: 11752030
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin and end-stage renal disease.
Markaki A; Psylinakis E; Spyridaki A
Hormones (Athens); 2016 Jul; 15(3):345-354. PubMed ID: 27838604
[TBL] [Abstract][Full Text] [Related]
5. Adiponectin and cardiovascular outcomes among hemodialysis patients.
Abdallah E; Waked E; Nabil M; El-Bendary O
Kidney Blood Press Res; 2012; 35(4):247-53. PubMed ID: 22286012
[TBL] [Abstract][Full Text] [Related]
6. Serum adiponectin and protein-energy wasting in predialysis chronic kidney disease.
Hyun YY; Lee KB; Oh KH; Ahn C; Park SK; Chae DW; Yoo TH; Cho KH; Kim YS; Hwang YH;
Nutrition; 2017 Jan; 33():254-260. PubMed ID: 27692989
[TBL] [Abstract][Full Text] [Related]
7. Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status.
Norata GD; Baragetti I; Raselli S; Stucchi A; Garlaschelli K; Vettoretti S; Piloni G; Buccianti G; Catapano AL
Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):56-63. PubMed ID: 19359150
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease.
Amira OC; Naicker S; Manga P; Sliwa K; Mia A; Raal F; Crowther NJ; Immelman RA; Olorunju S
Hemodial Int; 2012 Jan; 16(1):59-68. PubMed ID: 22099423
[TBL] [Abstract][Full Text] [Related]
9. Plasma adiponectin levels and clinical outcomes among haemodialysis patients.
Rao M; Li L; Tighiouart H; Jaber BL; Pereira BJ; Balakrishnan VS;
Nephrol Dial Transplant; 2008 Aug; 23(8):2619-28. PubMed ID: 18334528
[TBL] [Abstract][Full Text] [Related]
10. Adipocytokines in Patients with Chronic Kidney Disease Stage 5.
Yahya RS; Atwa MA; El-Sayed IH; El-Ghanaam DM; Hussein DT; El-Taweel FA
Clin Lab; 2016; 62(1-2):21-30. PubMed ID: 27012030
[TBL] [Abstract][Full Text] [Related]
11. High serum adiponectin concentration in children with chronic kidney disease.
Möller KF; Dieterman C; Herich L; Klaassen IA; Kemper MJ; Müller-Wiefel DE
Pediatr Nephrol; 2012 Feb; 27(2):243-9. PubMed ID: 21823040
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin levels and atherosclerotic risk factors in pediatric chronic peritoneal dialysis patients.
Bakkaloglu SA; Buyan N; Funahashi T; Pasaoglu H; Elhan AH; Hasanoglu E; Soylemezoglu O
Perit Dial Int; 2005; 25(4):357-61. PubMed ID: 16022092
[TBL] [Abstract][Full Text] [Related]
13. Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients.
Odamaki M; Furuya R; Kinumura Y; Ikegaya N; Kumagai H
Nephron Clin Pract; 2006; 102(1):c8-13. PubMed ID: 16166803
[TBL] [Abstract][Full Text] [Related]
14. Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients.
Spoto B; Mattace-Raso F; Sijbrands E; Pizzini P; Cutrupi S; D'Arrigo G; Tripepi G; Zoccali C; Mallamaci F
Nephrol Dial Transplant; 2013 Nov; 28 Suppl 4():iv181-7. PubMed ID: 23975745
[TBL] [Abstract][Full Text] [Related]
15. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients.
Ohashi N; Kato A; Misaki T; Sakakima M; Fujigaki Y; Yamamoto T; Hishida A
Intern Med; 2008; 47(6):485-91. PubMed ID: 18344634
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin Fractions Influence the Development of Posttransplant Diabetes Mellitus and Cardiovascular Disease in Japanese Renal Transplant Recipients.
Adachi H; Nakayama K; Hayashi N; Matsui Y; Fujimoto K; Yamaya H; Tonami H; Yokoyama H
PLoS One; 2016; 11(10):e0163899. PubMed ID: 27706207
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin and Cognitive Decline.
Rizzo MR; Fasano R; Paolisso G
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188008
[TBL] [Abstract][Full Text] [Related]
18. The role of serum magnesium and calcium on the association between adiponectin levels and all-cause mortality in end-stage renal disease patients.
Markaki A; Kyriazis J; Stylianou K; Fragkiadakis GA; Perakis K; Margioris AN; Ganotakis ES; Daphnis E
PLoS One; 2012; 7(12):e52350. PubMed ID: 23285003
[TBL] [Abstract][Full Text] [Related]
19. Relationship of high-molecular-weight adiponectin levels to visceral fat accumulation in hemodialysis patients.
Tamei N; Ogawa T; Ishida H; Ando Y; Nitta K
Intern Med; 2010; 49(4):299-305. PubMed ID: 20154435
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease.
Zoccali C; Mallamaci F; Tripepi G
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V67-72. PubMed ID: 15284363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
